Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07197554 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A Phase 1 study of Advanced Solid Tumors and Ewing Sarcoma, sponsored by SEED Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 171
- Enrollment target
- 6
- Study locations
NCT07197554: Recruiting Phase 1 study of Advanced Solid Tumors and Ewing Sarcoma, sponsored by SEED Therapeutics.
NCT07197554 is a Phase 1 study of Advanced Solid Tumors and Ewing Sarcoma that is actively recruiting participants, run by SEED Therapeutics. The registered enrollment target is 171 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (14% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07197554, a Phase 1 study of Advanced Solid Tumors and Ewing Sarcoma, is actively recruiting participants, sponsored by SEED Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 171 participants
- Enrollment target
- 6
- Study locations
Study Summary
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Primary Outcome
To characterize the safety, tolerability, and adverse event (AE) profile of escalating doses of ST-01156 administered for 5 consecutive days followed by 2 days without study drug administration every 7 days, with a cycle defined as 28 days (4 weeks).
Conditions Studied
Interventions
- DRUG ST-01156
Study Locations (6)
California
- The City of Hope National Medical Center - Duarte
- Hoag Memorial Hospital - Newport Beach
Massachusetts
- Mass General Brigham Cancer Institute - Boston
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 1 |
What NCT07197554 shows while recruiting
NCT07197554 is an interventional study that assigns participants to a tested intervention. The registered 171 participants enrollment target is mid-sized for trials with a published cap, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (14% lower).
The record links to 4 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ST-01156 is the first listed.
NCT07197554 lists 6 locations in 4 states (California, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT07197554 about?
NCT07197554 is a clinical study titled "A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies". A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
What is the current status of trial NCT07197554?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 171 participants. The study started on 2025-12-01. Estimated completion is 2029-12-31.
What conditions does trial NCT07197554 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC).
What interventions are being tested in trial NCT07197554?
The interventions under investigation include: ST-01156 (DRUG).
Who is sponsoring clinical trial NCT07197554?
This trial is sponsored by SEED Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07197554 being conducted?
This trial has 6 study locations across California, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07197554's enrollment target sits among peer trials
171 51st of 144 higher than 94 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02641145 · 171 participants · NA
Molecular Imaging of Primary Amyloid Cardiomyopathy
- NCT05541029 · 171 participants · NA
Music Listening: A Mechanistic Trial
- NCT05561127 · 171 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
- NCT05592938 · 171 participants · NA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI